Clinical Trials Browser

Withdrawn × Neurofibromatosis 1 × Clear all

Neurofibromatosis 1, Central Nervous System Neoplasms

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Clinical Trials

Stem Cells in NF1 Patients With Tumors of the Central Nervous System

PROTECT

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)